FOR IMMEDIATE RELEASE
Independent research firm publishes item-by-item recommendations on all six ballot measures within 48 hours of the company’s proxy filing.
NEW YORK, NY — Signal Proxy Intelligence, the independent proxy research line of Signal Corporate Intelligence, today published its recommendations for the Aug. 3, 2026 annual meeting of THERIVA BIOLOGICS, INC. (NYSE American:TOVX). SPI issued a recommendation on each of the six items on the ballot, published within 48 hours after the company’s definitive proxy statement was accepted on EDGAR.
Reviewing the ballot from the perspective of the common shareholder and using publicly available information only, SPI assigned the meeting a concern band of Routine. The firm recommends FOR on the advisory vote on executive compensation, citing that filing states current available shares are insufficient for awards needed over the next twelve months.
On the election of directors, SPI recommends FOR all one director nominee.
Signal Proxy Intelligence accepts no revenue from the companies it covers and publishes a recommendation on every ballot item within 48 hours of EDGAR acceptance.
The complete item-by-item analysis, including the rationale for each recommendation, is available at https://www.signallawgroup.com/wp-content/uploads/2026/07/spi-press-release-theriva-biologics-inc-0001104659-26-078859-2.pdf.
Ballot Summary: Recommendation by Item
| Item | Measure | SPI | Board |
|---|---|---|---|
| 1 | Election Of Directors | FOR | Board: FOR |
| 2 | To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026 | FOR | Board: FOR |
| 3 | To approve an amendment to the Company’s 2020 Stock Incentive Plan to increase the number of shares of Common Stock that it will have authority to grant under the plan to 6,500,000 shares of Common Stock | FOR | Board: FOR |
| 4 | To approve an amendment to the Company’s Articles of Incorporation to effect an increase the number of authorized shares of Common Stock to 450,000,000 shares | FOR | Board: FOR |
| 5 | To approve, pursuant to Section 713(a) of the NYSE American Company Guide and the terms of an inducement agreement, the issuance of up to an aggregate of 16,184,560 shares of Common Stock upon the exercise of the Company’s common stock purchase warrants issued to institutional investors in the Company’s private placement offering, which closed on October 17, 2025 | FOR | Board: FOR |
| 6 | To approve a proposal to adjourn the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Plan Increase Proposal, the Authorized Common Stock Increase Proposal and/or the Warrant Exercise Proposal | FOR | Board: FOR |
About Signal Proxy Intelligence
Signal Proxy Intelligence (SPI) is the proxy research line of Signal Corporate Intelligence, an independent research and investigations firm. SPI publishes FOR / AGAINST / WITHHOLD recommendations on every item of every covered proxy ballot, with a standing commitment to publish within 48 hours of EDGAR acceptance, analyzing each measure from the perspective of the common shareholder using publicly available information. SPI accepts no revenue from the companies it covers. Every recommendation is timestamped at publication, fingerprinted, and reconciled against the company’s reported vote.
Media contact
Rochelle Welner
contact@signallawgroup.com
Signal Proxy Intelligence is an operating company of Signal Law Group, an independent research and investigations firm. It is not a law firm, does not provide legal advice, and is not an investment adviser. This release reports research and analysis published for informational purposes only and does not constitute legal, investment, or voting advice for any person, account, or portfolio. References to Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC, unaffiliated entities and the holders of their respective trademarks, appear only where their positions are disclosed in the issuer’s proxy statement.
